Advances in diagnosis and treatment of malignant pleural mesothelioma

  • Giorgio Vittorio Scagliotti | giorgio.scagliotti@unito.it University of Turin, Department of Clinical & Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole, 10, I-10043 Orbassano (TO); University of Turin Department of Clinical and Biological Sciences Thoracic Oncology UNIT, San Luigi Hospital Orbassano (Torino), Italy.
  • Giovanni Selvaggi University of Turin Department of Clinical and Biological Sciences Thoracic Oncology UNIT, San Luigi Hospital Orbassano (Torino), Italy.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches which combine chemotherapy, surgery and radiotherapy. Combination chemotherapy represents the only resource available for advanced disease.The combination of cisplatin and pemetrexed is the treatment of choice. This review summarizes the latest developments in diagnostic techniques and the available therapeutic options for the management of MPM. Particular attention is given to the molecular basis of biologically targeted therapies to be used in the future.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-18
Info
Issue
Section
Reviews
Keywords:
Malignant Pleural Mesothelioma - Prognostic Factors - Mesothelin - Osteopontin - Chemotherapy - Pemetrexed - Targeted Therapy - Vascular Endothelial Growth Factor - Epidermal Growth Factor
Statistics
  • Abstract views: 1210

  • FULL TEXT: 182
How to Cite
Scagliotti, G. V., & Selvaggi, G. (2011). Advances in diagnosis and treatment of malignant pleural mesothelioma. Oncology Reviews, 1(2), 91-102. https://doi.org/10.4081/oncol.2007.144